Why the study?
Does trandolapril reduce mortality and hospital admissions in patients with left ventricular dysfunction after a myocardial infarction?
Does trandolapril reduce mortality and hospital admissions in patients with left ventricular dysfunction after a myocardial infarction?
Trandolapril administered for 2-4 years shortly after an MI in patients with left ventricular dysfunction provides sustained mortality and hospitalization benefits for at least 10-12 years.
Answers are grounded in this paper and cite their sources.
Supports prolonged ACE inhibitor use post-MI with LV dysfunction; extends short-term benefits to sustained 10-12-year mortality reduction.
AIMS: To investigate the long-term benefits of treatment with angiotensin-converting enzyme (ACE)-inhibitors in patients with myocardial infarction (MI) and left ventricular dysfunction (LVD). METHODS AND RESULTS: In the trandolapril cardiac evaluation (TRACE) study, 1749 patients with LVD (ejection fraction< or =35%) were randomized to trandolapril (n=876) or placebo (n=873) 3-7 days post-MI. Enrolment lasted from 1990 to 1994; on-treatment follow-up ranged from 2 to 4 years. At study closure, all patients were recommended continued ACE-inhibitor use. National registries were used to track deaths and hospitalizations until 2002. Mortality was analysed with Cox proportional hazard models and hospitalization with Poisson regression models (models adjusted for observation time). Over 10-12 years of follow-up, a total of 1283 deaths and 9220 hospitalizations were registered. Compared with the placebo group, the trandolapril group had a significantly reduced risk of all-cause mortality (relative risk 0.89, 95% CI 0.80-0.99, P=0.03), all-cause hospitalizations (rate ratio 0.92, 95% CI 0.88-0.96, P<0.001), and cardiovascular hospitalizations (rate ratio 0.95, 95% CI 0.91-1.00, P=0.047), including congestive heart failure hospitalizations (rate ratio 0.85, 95% CI 0.77-0.93, P<0.001). CONCLUSION: In patients with LVD, use of trandolapril shortly after an MI for 2-4 years has long-term benefits. The beneficial effect on mortality and hospitalization rates is maintained for at least 10-12 years.
No takes yet. Share an insight, caveat, or question.
Buch et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: